Compare AEO & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEO | HCM |
|---|---|---|
| Founded | 1977 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 1994 | N/A |
| Metric | AEO | HCM |
|---|---|---|
| Price | $26.97 | $13.40 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 12 | 1 |
| Target Price | ★ $20.70 | $13.75 |
| AVG Volume (30 Days) | ★ 9.7M | 24.9K |
| Earning Date | 12-02-2025 | 08-07-2025 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | 0.53 |
| Revenue | ★ $5,340,609,000.00 | $602,197,000.00 |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $1.78 | $15.54 |
| P/E Ratio | $22.01 | ★ $5.02 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.27 | $11.51 |
| 52 Week High | $25.57 | $19.50 |
| Indicator | AEO | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 81.03 | 26.13 |
| Support Level | $22.12 | $14.11 |
| Resistance Level | $24.66 | $13.79 |
| Average True Range (ATR) | 1.09 | 0.21 |
| MACD | 0.45 | -0.06 |
| Stochastic Oscillator | 99.76 | 11.59 |
American Eagle Outfitters Inc is a specialty retailer. The company is engaged in the retail of apparel and accessories with company stores in the United States, Canada, Mexico, and Hong Kong. The Company leases all store premises, regional distribution facilities, some of its office space, and certain information technology and office equipment. American Eagle also has its online business. It operates in two segments: American Eagle and Aerie. The majority of its revenue comes from its primary brand, American Eagle, which offers an assortment of specialty apparel, accessories, and personal care products for women and men. Geographically, it generates the majority of its revenue from the United States.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.